Algorae Pharmaceuticals (ASX: 1AI) has identified 90 high-quality drug-combination candidates following a preliminary review of newly delivered in silico synergy predictions generated by its upgraded AlgoraeOS v2 platform.
The platform evaluates cannabidiol in combination with more than 3,000 approved and investigational drugs across 170 cell lines.
The dataset spans more than 500,000 potential cannabidiol–drug–cell line combinations and incorporates confidence-weighted metrics that quantify both data-driven and model-driven uncertainty to refine downstream decision-making.
From this dataset, Algorae applied pre-specified prioritisation thresholds to select 90 candidates that balance predicted synergy with uncertainty reduction and biological generalisability.
Algorae reported that AlgoraeOS v2 outperformed representative state-of-the-art models, including those from Google DeepMind, across all major synergy metrics.
Powerful Candidate Advancement
Chief scientific officer Dr James McKenna said the combination of improved predictive capabilities and enhanced granularity provides a powerful approach for advancing candidates to validation assays.
“Together, these new tools will provide a powerful approach for prioritising candidates for further interrogation and progression to in vitro validation assays,” he added.
UNSW AI Institute associate professor Fatemeh Vafaee said AlgoraeOS v2 offers sovereign, high-performance capability that outperforms global state-of-the-art models while remaining lightweight and deployable.
She said its ability to generalise across diverse biological contexts and provide confidence-weighted outputs enhances clarity in selecting combinations for downstream validation.
Commercial and IP Considerations
Algorae will further prioritise potential candidates by incorporating commercial and intellectual-property considerations ahead of progressing selected combinations into preclinical validation assays.
The company has commenced discussions with the Peter MacCallum Cancer Centre regarding a second program and independent validation of AlgoraeOS v2 results.
These new in silico findings build on the independent preclinical validation of AlgoraeOS v1 at the centre announced on 5 December.
Algorae also continues to progress its commercial pharmaceutical business, with additional products and agreements moving through the pipeline.
The company received a $384,466.78 research and development tax incentive refund earlier this week, which it said reflects ongoing investment in AI-based approaches to pharmaceutical development and progression of its drug-candidate portfolio.
